XNAS · Healthcare · Biotechnology
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.10 | -0.59 | -490.00% | $2.4M | ❌ Miss | -5.23% | -9.92% | -9.62% |
| 2026-03-02 | Q4 2025 | -0.33 | -0.55 | -66.67% | $2.5M | ❌ Miss | +0.26% | +4.03% | +11.28% |
| 2025-11-06 |
| Q3 2025 |
| -0.31 |
| -0.26 |
| +16.13% |
| $27.6M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -0.48 | 0.03 | +106.25% | $48.7M | ✅ Beat | +6.91% | +17.60% | +23.77% |
| 2025-05-08 | Q1 2025 | -0.45 | -0.30 | +33.33% | $27.1M | ✅ Beat | — | — | — |
| 2025-03-05 | Q4 2024 | -0.09 | -0.31 | -244.44% | $31.0M | ❌ Miss | — | — | — |
| 2024-10-31 | Q3 2024 | -0.40 | -0.39 | +2.50% | $16.0M | ✅ Beat | — | — | — |
| 2024-08-01 | Q2 2024 | -0.19 | -0.49 | -157.89% | $19.2M | ❌ Miss | — | — | — |
Showing last 8 quarters.